8-K: OrthoPediatrics Corp. Announces Record Revenue and Improved Profitability for 2023

OrthoPediatrics Corp. reported a 22% increase in full-year revenue to $148.7 million and a significant improvement in adjusted EBITDA to $5.0 million for 2023.

Summary

• OrthoPediatrics Corp. announced its financial results for the fourth quarter and full year ended December 31, 2023.
• The company achieved record full-year revenue of $148.7 million, a 22% increase compared to $122.3 million in 2022.
• Fourth-quarter revenue reached $37.6 million, a 21% increase from $31.0 million in the same period last year.
• Domestic revenue grew by 24% in the fourth quarter and 20% for the full year, while international revenue increased by 13% in the fourth quarter and 26% for the full year.
• Adjusted EBITDA for the full year was $5.0 million, a significant improvement from $0.2 million in 2022.
• The company launched 8 new products in 2023 and completed the acquisition of Boston Orthotics & Prosthetics.
• OrthoPediatrics has reiterated its full-year 2024 revenue guidance to be in the range of $197.0 million to $200.0 million, representing growth of 32% to 34% compared to 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and strategic acquisitions. While there is a net loss, the underlying performance and future guidance are encouraging.

Positives

• The company experienced strong revenue growth across all segments, including trauma and deformity, scoliosis, and the newly acquired OPSB.
• Gross profit margin improved slightly to 74.8% for the full year 2023.
• The company's adjusted EBITDA significantly improved year-over-year, indicating better profitability.
• OrthoPediatrics has a diverse business with strength across all segments.
• The company is capturing market share in both trauma and deformity and scoliosis businesses.
• The acquisition of Boston Orthotics & Prosthetics is expected to contribute to future growth.
• The company has strengthened its balance sheet with $80 million in debt financing.
• The company has reiterated strong revenue guidance for 2024.

Negatives

• The company reported a net loss of $21.0 million for the full year 2023, compared to a net income of $1.3 million in the previous year.
• Operating expenses increased by 19% for the full year, driven by increased sales volume and personnel costs.
• Net loss per share for the full year was $0.92, compared to net income of $0.06 per share in 2022.
• International scoliosis sales were lower than expected in the fourth quarter due to reduced orders from stocking distributors in South America.
• The company experienced cancelled cases due to late December RSV infections.

Risks

• The company's future performance is subject to risks related to COVID-19 and its impact on demand.
• The company's ability to respond to challenges related to the pandemic is a risk factor.
• The company's financial results could be affected by factors set forth in their annual report on Form 10-K.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects full-year 2024 revenue to be in the range of $197.0 million to $200.0 million, representing growth of 32% to 34% over 2023 revenue, and adjusted EBITDA to be between $8.0 million and $9.0 million.

Management Comments

• 2023 was another strong year for OrthoPediatrics as we delivered record top-line results and outperformed our adjusted EBITDA expectations.
• We continue to benefit from an extremely diverse business from which we saw strength across all segments this year.
• Both our trauma and deformity and scoliosis businesses continue to capture market share and drive growth.
• Looking ahead, we believe we are in an extremely strong position for 2024 and we have the right drivers in place to sustain our strong revenue and profitability growth.
• We look forward to helping the next million kids with our portfolio of the most advanced pediatric orthopedic solutions.

Industry Context

This announcement reflects a positive trend in the pediatric orthopedics market, with OrthoPediatrics demonstrating strong growth and market share gains. The acquisition of Boston Orthotics & Prosthetics also indicates a strategic move to expand into related areas of pediatric care.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, OrthoPediatrics' 22% revenue growth and significant improvement in adjusted EBITDA suggest a strong performance compared to industry averages.
• The company's focus on pediatric orthopedics and its comprehensive product offering position it well against competitors with broader product portfolios.
• The acquisition of Boston Orthotics & Prosthetics is a strategic move that differentiates OrthoPediatrics from competitors focused solely on surgical solutions.
• The company's growth in both domestic and international markets indicates a strong global presence and potential for further expansion.
• The launch of 8 new products in 2023 demonstrates a commitment to innovation and product development, which is crucial for maintaining a competitive edge.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved profitability positively.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to a broader range of pediatric orthopedic solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• OrthoPediatrics will host a conference call on March 7, 2024, to discuss the results.
• The company will continue to focus on expanding its product portfolio and market share.
• The company will integrate Boston Orthotics & Prosthetics into its operations.

Key Dates

Keywords

OrthoPediatrics, pediatric orthopedics, revenue, EBITDA, financial results, medical devices, acquisitions, growth, scoliosis, trauma, deformity, orthotics, bracing